Healthcare is a major component of the contemporary welfare state, and thus ensuring public health through product safety is a substantive public concern.
KeywordsEuropean Union Member State European Union Member State Social Health Insurance Pharmacovigilance System
- Andrews, E., Moore, N. (2014). Mann’s Pharmacovigilance. Wiley-Blackwell, Oxford.Google Scholar
- Belton, K. J. and the European Pharmacovigilance Group (1997). Attitude Survey of Adverse Drug-Reaction Reporting by Health Care Professionals across the European Union. European Journal of Pharmacology 52: 423-427.Google Scholar
- Borg, J. J., Tanti, A., Kouvelas, D., Lungu, C., Prozynski, M., Serracino-Inglott, A., Aislaitner, G. (2015). European Union Pharmacovigilance Capabilities: Potential for the New Legislation. Therapeutic Advances in Drug Safety 6 (4): 120-140.Google Scholar
- Burau, V., Blank, R. H. (2006). Comparing Health Policy: An Assessment of Typologies of Health Systems. Journal of Comparative Policy Analysis 8 (1): 63–76.Google Scholar
- Cabiedes, L., Guillén, A. (2001). Adopting and Adapting Managed Competition: Health Care Reform in Southern Europe. Social Science and Medicine 52: 1205-1217.Google Scholar
- Calvo, B., Zuňiga, L. (2014). EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars. Drug Safety 37: 9-18.Google Scholar
- Drozd, M., Szkultecka-Dębek, M., Baran-Lewandowska, I. (2014). Biosimilar Drugs – Automatic Substitution Regulations Review. Polish ISPOR Chapter’s Therapeutic Programmes and Pharmaceutical Care (TPPC) Task Force Report. Journal of Health Policy 1: 52-57.Google Scholar
- Dubois, C.-A., McKee, M. (2004). Health and Health Care in the Candidate Countries of the European Union: Common Challenges, Different Circumstances, Diverse Policies. McKee, M., MacLehose, L., Nolte, E. (eds) (2004). Health Policy and European Union Enlargement. Maidenhead: Open University Press: 43-63.Google Scholar
- European Commission (2016). Pharmacovigilance Related Activities of Member States and the European Medicines Agency Concerning Medicinal Products for Human Use (2012-2014), COM(2016) 498 final, Brussels, 08.08.2016.Google Scholar
- Guillén, A. M., Matsaganis, M. (2000). Testing the ‘Social Dumping’ Hypothesis in Southern Europe: Welfare Policies in Greece and Spain During the Last 20 Years. Journal of European Social Policy 10 (2): 120-145.Google Scholar
- Moran, M. (1999) Governing the Health Care State: A Comparative Study of the United Kingdom, the United States and Germany. Manchester: Manchester University Press.Google Scholar
- SCOPE (2016). Work Package 4 – ADR Collection.Google Scholar
- Vermeer, N. S., Spierings, I., Mantel-Teeuwisse, A. K., Straus, S. M. J. M., Giezen, T. J., Leufkens, H. G. M., Egberts, T. C. G., De Bruin, M. L. (2015). Traceability of Biologicals: Present Challenges in Pharmacovigilance. Expert Opinion on Drug Safety, 14 (1).Google Scholar
- Wendt, C., Frisina, L., Rothgang, H. (2009). Healthcare System Types: A Conceptual Framework for Comparison. Social Policy and Administration 43 (1): 70-90.Google Scholar
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.